facebook
Traded Co logo
Submit
Daily limit: 0/10

United Therapeutics Acquires Office Building In Durham NC For $107 Million From W. Daniel Faulk Jr

Property Image
SOLD
$107,000,000

North Carolina

See Similar Deals
Office400,000 SF
Sold 09/19/2025
the dealdetailscomps
Property Image
SOLD

United Therapeutics Acquires Office Building In Durham NC For $107 Million From W. Daniel Faulk Jr

79 T.W. Alexander Drive

See Similar Deals
Office400,000 SF
Sold 09/19/2025

Summary

NORTH CAROLINA
Asset Type:Office
Price Per Square Foot:$267
Total Square Footage:400,000 SF
Transaction Type:Sale

The property involved in this transaction is located at 79 T.W. Alexander Drive in Durham, NC. It is categorized as an office asset, encompassing a total square footage of 400,000. The sale price for this property was $107,000,000, which translates to a price per square foot of $268.

Summary of transaction details:

  • Property Type: Office
  • Transaction Amount: $107,000,000
  • Buyer: United Therapeutics
  • Seller: W. Daniel Faulk, Jr. - Oxford Properties Group
  • Square Footage: 400,000
  • Price per Square Foot: $268
  • Date of Sale: 09/19/2025
  • Market: Durham, NC

The transaction involved United Therapeutics as the buyer, which is expanding its footprint in Research Triangle Park to a total of 1.4 million square feet. W. Daniel Faulk, Jr. represented the seller, Oxford Properties Group. The acquisition included five office and lab buildings, enhancing United Therapeutics' investments in the area. Furthermore, the biotech company is also developing a $500 million Tyvaso-DPI manufacturing facility in the vicinity.

Players

SELLER

Details

SOLD
IMAGE: 09/19/2025 ADDRESS: 79 T.W. Alexander Drive MARKET: Durham, NC ASSET TYPE: Office BUYER: United Therapeutics SELLER: W. Daniel Faulk, Jr. - Oxford Properties Group SALE PRICE: $107,000,000 SF: 400,000 ~ PPSF: $268 NOTE: United Therapeutics bought five office and lab buildings in Research Triangle Park for $107 million, expanding its footprint there to 1.4 million square feet. The deal adds to the biotech’s growing investments in RTP, where it is also building a $500 million Tyvaso-DPI manufacturing facility.

Stay in the Know

Subscribe for insider commercial real estate news, deal highlights, and market insights—delivered straight to your inbox.

By subscribing, you agree to our Terms of Service and Privacy Policy.

Similar Deals

Suggestions
CRE CalculatorAnalyze deals based on income, expenses, and financing. We automatically filled the calculator with data from the deal you are viewing, fill free to modify it to see how it affects the results.
Deal Type
Operating Income
Operating Expenses (Annual)
Net Operating Income (NOI)

$5,706,666.67

Debt Service Coverage Ratio (DSCR)

0.94x

Cap Rate

5.33%

Cash Flow (Annual)-$380,148.39
Cash-on-Cash Return-1.27%
Monthly Debt Service$507,234.59
Annual Debt Service$6,086,815.07